Jeff Evans has been editor of Rheumatology News/MDedge Rheumatology and the EULAR Congress News since 2013. He started at Frontline Medical Communications in 2001 and was a reporter for 8 years before serving as editor of Clinical Neurology News and World Neurology, and briefly as editor of GI & Hepatology News. He graduated cum laude from Cornell University (New York) with a BA in biological sciences, concentrating in neurobiology and behavior.
News
Model may predict prolonged status epilepticus outcomes
The two-variable model must now undergo external validation.
News
ACR forges ahead with physician-focused APM for RA
CHICAGO – A work group is determining cost and payment details through surveys and a financial analysis of two large practices.
News
3-D model neurovascular unit developed with working blood-brain barrier
The model could have potential applications in drug discovery, toxicity screening, and disease modeling.
News
Benign MS is real in small minority of patients
But benign disease tracks poorly with disability measures and lacks agreement between patients and physicians.
News
Cost of medical care for older adults with epilepsy steadily grows
In the United States, costs during 2003-2014 were nearly twice as high as they were for those without epilepsy.
Audio
MS drugs in Medicare Part D: Higher tiers, less coverage, more prior authorizations
LOS ANGELES – The 2007-2016 analysis includes 11 drugs falling under Medicare Part D.
Video
VIDEO: Meeting stroke screening demand will require systems’ reorganization
LOS ANGELES – Telestroke triage of patients by comprehensive stroke centers is the way to go, says Dr. Lawrence Wechsler.
Video
VIDEOS: High-priced drugs, out-of-pocket costs raise challenges for neurologists
LOS ANGELES – Members of the AAN Neurology Drug Pricing Task Force spoke about the issues that arise in getting patients access to high-cost drugs...
News
Real-world data so far support pimavanserin trial results
LOS ANGELES – Two studies report on clinicians’ experiences with 105 patients.
News
Blood-brain barrier health may signal early loss of MS treatment response
A single dynamic contrast-enhanced MRI scan at 6 months was predictive in patients taking natalizumab or fingolimod.